• CAR T-cell therapy involves modifying the T-cells in the body so that they attack the leukaemia cells more efficiently.
  • Tisagenlecleucel is a CAR T-cell therapy developed to identify and eliminate leukaemia cells which have the CD19 protein. It is the first approved CAR T‑cell for the treatment of ALL.
  • Tisagenlecleucel is recommended for the treatment of patients with relapsed or refractory B-cell ALL in people aged up to 25 years.